介紹：癌抗原19-9指一種與胰腺癌、膽囊癌、結(jié)腸癌和胃癌等相關(guān)的腫瘤標(biāo)志物，又稱胃腸道相關(guān)抗原。癌抗原19-9對(duì)胰腺癌有較高的靈敏度和較好的特異性，其陽性率在85%-95%之間，且隨手術(shù)后與病情好轉(zhuǎn)而降低。
CA19-9是糖抗原的一種，其水平升高大多預(yù)示有胰腺炎、肝硬化、糖尿病、消化道腫瘤的可能。
CA19-9的定標(biāo)標(biāo)準(zhǔn)值:0-40之間(單位:kU/L)
糖鏈抗原19-9升高見于:
1. 大部分胰腺癌患者血清CA19-9水平明顯增高;
2. 肝膽系癌、胃癌、結(jié)直腸癌的CA19-9水平也會(huì)升高;
3. 低濃度增高、糖鏈抗原19-9升高可見于慢性胰腺炎、膽石癥、肝硬化、腎功能不全、糖尿病等。
臨床應(yīng)用：
CA19-9是胰腺癌和結(jié)、直腸癌的標(biāo)志物，血清癌抗原19-9可作為胰腺癌，膽囊癌等惡性腫瘤的輔助診斷指標(biāo)。胚胎期胎兒的胰腺、膽囊、肝、腸等組織存在這種抗原，正常人體組織中含量很低；在消化道惡性腫瘤，尤其是胰腺癌、膽囊癌病人血清中，癌抗原19-9含量明顯增高，但早期診斷價(jià)值不大，主要作為病情監(jiān)測(cè)和預(yù)示復(fù)發(fā)的指標(biāo)。此外，對(duì)消化道疾病鑒別診斷（如胰腺癌與胰腺炎。胃癌與胃潰瘍）亦有一定價(jià)值。
增高：見于胰腺癌、膽囊癌、胃癌、結(jié)腸癌、肝癌等;急性胰腺炎、膽囊炎、肝炎等也有不同程度的升高。
名稱：CA19-9（癌抗原19-9）腫瘤標(biāo)志物相關(guān)抗體
別名：CA19-9（癌抗原19-9）腫瘤標(biāo)志物，CA199，Carbohydrate antigen199, Carbohydrate antigen 19-9，癌抗原19-9，Anti CA19-9
鏈接：https://www.antibodysystem.com/index/search?wd=CA19-9
其他產(chǎn)品：
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A297) (MHK33901)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A298) (MHK33902)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A299) (MHK33903)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A300) (MHK33904)
Anti-sLea/CA19-9 Antibody (1116NS19.9) (FHK33910)
Anti-sLea/CA19-9 Antibody (7E3#) (FHK33920)
InVivoMAb Anti-sLea/CA19-9 Antibody (Iv0123) (VHK33901)
Anti-sLea/CA19-9 Antibody (SAA0808) (RHK33901)
Research Grade Anti-Human CA19-9/Sialyl Lewis A (sLe A) Antibody (MVT-5873) (DHK33901)
形式：Liquid
純度：>95%
用途范圍：僅用于科研
儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
AntibodySystem：
AntibodySystem是由法國ProteoGenix專家團(tuán)隊(duì)創(chuàng)立的科研試劑品牌，產(chǎn)品管線覆蓋各種病毒研究蛋白/抗體質(zhì)控品、Invivo功能性抗體，流式抗休、抗藥藥物靶點(diǎn)蛋白以及其他活性蛋白、PEG抗體，磷酸化抗體、抗DNA抗體、小分子抗體、RUO ELISA試劑盒、生物類似物。
佰樂博生物：法國ProteoGenix、Antibodysystem品牌亞洲區(qū)獨(dú)家運(yùn)營代理商
產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757
郵箱：biolab-reagents@atagenix.com
QQ：2663991332
參考文獻(xiàn)：
CA 19-9: Biochemical and Clinical Aspects. PMID: 26530370
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. PMID: 29282264
CA19-9 and CEA biosensors in pancreatic cancer. PMID: 38246211
[CA19-9]. PMID: 10778164
Monitoring Ca19-9 during pancreatic cyst surveillance: Better safe than sorry? PMID: 37573577
[CA19-9: more than just a biomarker?]. PMID: 31931544
CA19-9: the Italian experience. PMID: 7846014
Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma. PMID: 36915042
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. PMID: 26576628
[Elevated CA19-9 levels; not always cancer]. PMID: 33651490
The clinical significance of elevated levels of serum CA 19-9. PMID: 15190651
CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. PMID: 37909951
Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis. PMID: 35733415
Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection. PMID: 35138217
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. PMID: 30466797
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. PMID: 27692554
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer. PMID: 29038848
Electrochemical Immunoassay for Tumor Marker CA19-9 Detection Based on Self-Assembled Monolayer. PMID: 35889454
Glycoprotein CA19.9-specific monoclonal antibodies recognize sialic acid-independent glycotope. PMID: 29072130
Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. PMID: 31000337
CA19-9-producing transitional cell carcinoma of the renal pelvis: a case report. PMID: 11329962
High level of tumor marker CA19-9 returned to normal after cholecystectomy in calculous cholecystitis patients. PMID: 36644950
Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions. PMID: 36826082
High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma. PMID: 30591483
[CA19-9 has no value as a tumor marker in obstructive jaundice]. PMID: 10065510
CA19-9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy. PMID: 38263014
Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. PMID: 34119488
Predictive Value of Preoperative Serum CA19-9 on Margin Status. PMID: 31638508
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. PMID: 33047181
Combination of preoperative CA19-9 levels, cell differentiation, and age predicts survival for patients with gastric cancer before surgery. PMID: 34889247
[Bronchioloalveolar carcinoma producing CA19-9]. PMID: 21682047
A Rare Cause of Elevated Serum CA19-9. PMID: 32828817
Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. PMID: 28803454
[CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?]. PMID: 29644426
SERS-based immunoassay and degradation of CA19-9 mediated by gold nanowires anchored magnetic-semiconductor nanocomposites. PMID: 33265038
Comment re: "Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping". PMID: 28434838
Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. PMID: 22411488
A Case of Pseudoelevation of Serum CA19-9 Level. PMID: 38213206
The implication of tumor biomarker CA19-9 in the diagnosis of intracranial epidermoid cyst. PMID: 27793056
Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. PMID: 21601881
